abstract |
The present invention provides GSK3β variants, including splice variants expressed in bone or other tissues. These variants have a broad range of functional activity, from inhibiting the Wnt pathway to activating the pathway as dominant-negatives of the full-length GSK3β. These variants, as well as their modulators, can be used to treat diseases that involve GSK3β or its associated signaling pathways. |